The psychiatric-mental health nurse practitioner (PMHNP) meets with a new client for an evaluation. The client recently lost her older sister, and she remarks how much the PMHNP reminds her of her sister. At one point, she even calls the PMHNP by the sister's name. The PMHNP is concerned the new client could have the potential to experience which of the following?

Choice A reason: The orientation phase is the initial stage of the therapeutic relationship where the client and therapist establish rapport, clarify roles, and set goals. It is typically marked by anxiety and uncertainty, but not regression or symptom reemergence. The client is just beginning to engage and is unlikely to show deep psychological shifts at this point.

Choice B reason: The termination phase involves ending the therapeutic relationship. While it may evoke emotional responses such as sadness or anxiety, it is not typically associated with regression or the reemergence of symptoms. Instead, it focuses on consolidating gains and planning for future coping strategies.

Choice C reason: The working phase is where the core therapeutic work occurs. This phase involves exploring painful emotions, unresolved conflicts, and maladaptive behaviors. It is common for clients to regress or experience a resurgence of symptoms during this phase as they confront difficult material. This regression is often a sign of progress, indicating that the client is engaging deeply with the therapeutic process.

Choice D reason: Identification is a subcomponent of the working phase in Peplau’s theory, where the client begins to respond selectively to those who can meet their needs. While it is part of the therapeutic process, it is not the primary phase associated with regression or symptom reemergence. The broader working phase encompasses these dynamics more fully.

Choice A reason: While melatonin is generally considered safe for short-term use, it has clinically significant interactions with several medications, including immunosuppressants. It can stimulate immune function, which may counteract the effects of immunosuppressive therapy. Therefore, this response is overly dismissive and potentially unsafe.

Choice B reason: Melatonin can interfere with immunosuppressive therapy by enhancing immune activity, which is counterproductive in conditions like rheumatoid arthritis where immunosuppression is often necessary. This makes it contraindicated or at least a cautionary supplement in such contexts. The PMHNP should recognize this and advise accordingly.

Choice C reason: While deferring to the primary care provider may seem prudent, the PMHNP is qualified to assess drug interactions and should take responsibility for evaluating the safety of melatonin in this context. This response lacks clinical assertiveness.

Choice D reason: Suggesting a benzodiazepine as a replacement for melatonin without assessing the client’s full psychiatric and medical profile is inappropriate. Benzodiazepines carry risks of dependence and sedation and are not a direct substitute for melatonin in most cases.